Assessment of Myocardial Fibrosis Using Two-Dimensional and Three-Dimensional Speckle Tracking Echocardiography in Dilated Cardiomyopathy with Advanced Heart Failure
This study aimed to depict strain parameters derived from two-dimensional (2D)- and three-dimensional speckle tracking echocardiography (3D-STE) and to explore which may best reflect myocardial fibrosis (MF) in dilated cardiomyopathy (DCM) with advanced heart failure (HF), by comparing with histological fibrosis. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 14, 2021 Category: Cardiology Authors: Jing Wang, Yanting Zhang, Li Zhang, Fangyan Tian, Bin Wang, Yuji Xie, Wei Sun, Zhenxing Sun, Yali Yang, Qing Lv, Nianguo Dong, Yuman Li, Mingxing Xie Source Type: research

Catabolic/anabolic imbalance is accompanied by changes of LV steroid nuclear receptor expression in tachycardia-induced systolic heart failure in male pigsSteroid hormones in pig model of heart failure
: Steroid hormones play an important role in heart failure (HF) pathogenesis, and clinical data has revealed disordered steroidogenesis in male HF patients. However, there is still a lack of studies on steroid hormones and their receptors during HF progression. Therefore, a porcine model of tachycardia-induced cardiomyopathy corresponding to HF was used to assess steroid hormone concentrations in serum and their nuclear receptor levels in heart tissue during the consecutive stages of HF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 12, 2021 Category: Cardiology Authors: Maciej Zacharski, Alicja Tomaszek, Liliana Kiczak, Maciej Ugorski, Jacek Bania, Urszula Pas ławska, Ilona Rybinska, Ewa Anita Jankowska, Adrian Janiszewski, Piotr Ponikowski Source Type: research

Understanding longitudinal changes in pulmonary vascular resistance after left ventricular assist device implantation
: Elevated PVR is common in patients with advanced heart failure. PVR generally improves after LVAD implantation, but the rate of decrease has not been quantified and the patient characteristics most strongly associated with this improvement are unknown. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 12, 2021 Category: Cardiology Authors: Gaurav Gulati, Robin Ruthazer, David DeNofrio, Amanda R. Vest, David Kent, Michael S. Kiernan Source Type: research

Dynamic Correlation Between Cardiac Filling Pressures And B-Lines In Lung Ultrasound: A Pilot Study
The number of B-lines in lung ultrasound (LUS) is a surrogate of pulmonary congestion, that helps establishing the diagnosis of heart failure (HF)1, and serves as a powerful predictor of worse outcomes in the ambulatory setting2. Moreover, a LUS-guided therapy has the potential to improve prognosis after a HF hospitalization3. Previous studies showed a correlation between the number of B-lines and pulmonary capillary wedge pressure (PCWP) about 0.50 4,5. However, data on the change in the number of B-lines in response to dynamic variation of pulmonary and cardiac pressures are scarce. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 8, 2021 Category: Cardiology Authors: Mercedes Rivas-Lasarte, Eduard Sol é-González, Jesús Álvarez-García, Alba Maestro, Joan Garcia-Picart, Eulalia Roig, Juan Cinca Source Type: research

Biomarkers and their relation to cardiac function late after peripartum cardiomyopathy
Angiogenic imbalance involving the placental protein soluble Fms-like tyrosine kinase-1 (sFlt-1) and cleavage of the nursing-hormone prolactin by the enzyme cathepsin D (CD) both play a role in the pathogenesis of peripartum cardiomyopathy (PPCM). We hypothesized that angiogenic imbalance and increased activity of CD have a long-lasting impact in women with PPCM. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 7, 2021 Category: Cardiology Authors: Anne S. Ersb øll, Jens P. Goetze, Marianne Johansen, Maria G. Hauge, Karen Sliwa, Niels Vejlstrup, Finn Gustafsson, Peter Damm Source Type: research

Editorial Board
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2021 Category: Cardiology Source Type: research

Table of Contents
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2021 Category: Cardiology Source Type: research

Masthead
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2021 Category: Cardiology Source Type: research

Social Media as Ethical Obligation
Online behavior is in a state of rapid transition with the Internet at present evolving into a major source of medical information for the consumer.1,2 It is critical that we in Cardiology are cognizant of this and comprehend the impact this has on consumer insight and on patient behavior and compliance. Two research letters in this issue highlight the potential application and opportunity of our understanding. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2021 Category: Cardiology Authors: Farris K. Timimi Tags: Editorial Source Type: research

The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation
We (Anu and Rob) first met at the annual scientific meeting for the Heart Failure Society of America (HFSA) back in 2012, where we were fortunate to forge a professional and personal friendship. What we loved about the HFSA back then (and appreciate even more now) is its holistic and multidisciplinary approach to education, advocacy and care delivery. Here, we enjoy a close-knit community with a patient-centered focus. As such, we consider the HFSA our “societal home.” As the official journal of the Society, JCF is uniquely positioned to positively influence how HF care is delivered and practiced by nurses, pha...
Source: Journal of Cardiac Failure - January 1, 2021 Category: Cardiology Authors: Anuradha Lala, Robert J. Mentz Tags: Editor's Page Source Type: research

Acknowledgment of Reviewers 2020
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2021 Category: Cardiology Source Type: research

Pregnancy Associated Heart Failure with Preserved Ejection Fraction (HFpEF): Risk Factors and Maternal Morbidity
Pregnancy-related maternal mortality has more than doubled in the last quarter century from 7.2 deaths/100,000 live births in 1987 to 16.9 deaths/100,000 live births in 2016. (1) Cardiovascular disease is recognized as the leading contributor. (1-3) Moreover, severe maternal morbidity is rising. (4, 5) Mechanisms driving increasing maternal morbidity are not fully understood, however older maternal age, obesity and chronic conditions such as diabetes and hypertension are potential culprits. (6) (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 31, 2020 Category: Cardiology Authors: Joan E. Briller, Mulubrhan F. Mogos, James M. Muchira, Mariann R. Piano Source Type: research

A Case-Control Study of Peripartum Cardiomyopathy Using the Rochester Epidemiology Project
Peripartum cardiomyopathy (PPCM) is defined as the development of cardiac failure in the last month of pregnancy or within 5 months of delivery in women with no history of heart disease and no other identifiable cause for cardiac failure. PPCM is characterized by left ventricular (LV) systolic dysfunction with LV ejection fraction (LVEF) ≤45% confirmed by echocardiography1 as well as heart failure symptoms. Women with PPCM can experience complete recovery of heart function2,3 with early diagnosis and treatment. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 31, 2020 Category: Cardiology Authors: Erika J. Douglass, Jr. Leslie T. Cooper, A. Carolina Morales-Lara, Demilade A. Adedinsewo, Todd D. Rozen, Lori A. Blauwet, DeLisa Fairweather Source Type: research

Risk Prediction for Peripartum Cardiomyopathy in Delivering Mothers: A Validated Risk Model
: Peripartum cardiomyopathy (PPCM) causes significant morbidity and mortality in childbearing women. Delays in diagnosis lead to worse outcomes; however, no validated risk prediction model exists. We sought to validate a previously described model and identify novel risk factors for PPCM presenting at the time of delivery. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 31, 2020 Category: Cardiology Authors: Melinda B. Davis, Jennifer Jarvie, Ellise Gambahaya, JoAnn Lindenfeld, David Kao Source Type: research

Effects of low-level tragus stimulation on endothelial function in heart failure with reduced ejection fraction
Heart failure with reduced ejection fraction (HFrEF) is associated with a 50% mortality within 5 years.1 Development of novel treatment strategies is imperative to improve clinical outcomes. HFrEF is associated with sympathovagal imbalance leading to inflammation, oxidative stress, and endothelial dysfunction (EnD).2-6 Both macrovascular EnD and microcirculatory impairment are common in HFrEF.4,7 Direct vagus nerve stimulation (VNS) studies in HFrEF have yielded mixed results.8 Transcutaneous stimulation of the auricular branch of the vagus nerve (ABVN), which innervates the tragus, has emerged as an alternative to direct ...
Source: Journal of Cardiac Failure - December 30, 2020 Category: Cardiology Authors: Tarun W. Dasari, Tamas Csipo, Faris Amil, Agnes Lipecz, Gabor A. Fulop, Yunqiu Jiang, Rajesh Samannan, Sarah Johnston, Yan D. Zhao, Federico Silva-Palacios, Stavros Stavrakis, Andriy Yabluchanskiy, Sunny S. Po Source Type: research

Impact of Right Atrial Remodeling in Heart Failure with Preserved Ejection Fraction
Approximately one-half of heart failure (HF) patients have a preserved ejection fraction (HFpEF).1 The HFpEF pathophysiology is complex, and this disorder has been increasingly characterized as a heterogeneous syndrome that is caused or exacerbated by a variety of cardiac and extracardiac abnormalities.2,3 The importance of the right heart in HFpEF is currently well appreciated.4 Right ventricular (RV) dysfunction is common and contributes to reduced aerobic capacity and poor prognosis in patients with HFpEF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 29, 2020 Category: Cardiology Authors: Takahiro Ikoma, Masaru Obokata, Kenya Okada, Tomonari Harada, Hidemi Sorimachi, Kuniko Yoshida, Toshimitsu Kato, Koji Kurosawa, Masahiko Kurabayashi, Masami Murakami Source Type: research

Phosphodiesterase-5 Inhibitors and Outcomes During Left Ventricular Assist Device Support: A Systematic Review and Meta-Analysis
Left ventricular assist device (LVAD) therapy has revolutionized the treatment of end-stage heart failure (HF) over the past decade1. Despite its clear benefits in improving survival and quality of life, device-related complications, most notably right ventricular failure (RVF) and hemocompatibility-related adverse events (HRAE) including bleeding and thrombosis, are common and deleterious1,2. As LVADs are commonly used in patients with advanced HF, interventions to minimize these major complications have been sought. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 29, 2020 Category: Cardiology Authors: Veraprapas Kittipibul, Vanessa Blumer, Natthapon Angsubhakorn, Gabriel A. Hernandez, Sandra Chaparro, Ryan J. Tedford, Richa Agarwal Source Type: research

Case Reports of Implantable Cardiac Device Physiologic Sensor Changes in Subjects with COVID-19 Infection
We report on a unique pattern of sensor deviations that appear to occur specifically with SARS-CoV-2 infection. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 28, 2020 Category: Cardiology Authors: Jessica L. Shumway, Craig M. Stolen, Rezwan Ahmed, Marie Plumer, Robert C. Capodilupo Tags: Brief Report Source Type: research

Limited balloon atrial septostomy for left ventricular unloading in peripheral extracorporeal membrane oxygenation
This study describes the authors ’ experience with a limited balloon atrial septostomy (BAS) technique, using a median balloon size of 15 mm, as a left ventricular (LV) unloading strategy in veno-arterial extracorporeal membrane oxygenation (VA-ECMO). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 21, 2020 Category: Cardiology Authors: Kaushik Amancherla, Jonathan N. Menachem, Ashish S. Shah, JoAnn Lindenfeld, Jared O'Leary Tags: Brief Report Source Type: research

Effects of Depression on Heart Failure Self-Care
This study was designed to clarify the relationship between depression and self-care in hospitalized patients with HF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 21, 2020 Category: Cardiology Authors: Kenneth E. Freedland, Judith A. Skala, Brian C. Steinmeyer, Robert M. Carney, Michael W. Rich Source Type: research

Bariatric Surgery in Patients with Obesity and Ventricular Assist Devices Considered for Heart Transplantation: Systematic Review and Individual Participant Data Meta-analysis
: Class II obesity ( ≥ 35 kg/m2) is a contraindication for heart transplantation (HT). Although few single-center studies (case reports/series and small cohorts) have reported promising outcomes of bariatric surgery (BS) in patients with obesity and ventricular assist devices (VADs), low sample sizes have made their a nalysis and interpretation challenging. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 21, 2020 Category: Cardiology Authors: Adrian daSilva deAbreu, Bader Aldeen Alhafez, Yuhamy Curbelo-Pena, Carl J. Lavie, Hector O. Ventura, Juan Francisco Loro-Ferrer, Stacy A. Mandras Tags: Review Article Source Type: research

Influence of Donor Transmitted and Rapidly Progressive Coronary Vascular Disease on Long Term Outcomes After Heart Transplantation: A Contemporary Intravascular Ultrasound Analysis
Donor transmitted atherosclerosis (DTA) and rapidly progressive cardiac allograft vasculopathy (CAV) at 1-year are intravascular ultrasound (IVUS)-derived measures shown to predict adverse cardiovascular outcomes in the setting of early generation immunosuppressive agents. Given the paucity of data on the prognostic value of IVUS-derived measurements in the current era, we sought to explore their association with adverse outcomes after heart transplantation. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 21, 2020 Category: Cardiology Authors: Brett W. Sperry, Raed Qarajeh, Mohamed A. Omer, Hunter Brandt, David Safley, A. Michael Borkon, Mark P Everley, Timothy J Fendler, Taiyeb M Khumri, Stephanie L Lawhorn, Anthony Magalski, Michael E. Nassif, Deepthi Vodnala, Andrew C. Kao, Bethany A. Austin Source Type: research

Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy
PIONEER-HF established the safety and efficacy of in-hospital initiation of the angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril-valsartan (S/V), in patients with acutely decompensated heart failure (ADHF) after hemodynamic stabilization. Patients were off intravenous (IV) vasodilators for 6 hours and inotropes for 24 hours pre-study enrollment.1 We recently demonstrated in selected ADHF patients with low cardiac output (CO) that S/V can be used as oral vasodilator when guided by invasive hemodynamic monitoring. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 21, 2020 Category: Cardiology Authors: Trejeeve Martyn, Kathleen D. Faulkenberg, Chonyang L. Albert, Zachary J. Il'Giovine, Varinder K. Randhawa, Eoin Donnellan, Venu Menon, Jerry D. Estep, Steven E. Nissen, W.H. Wilson Tang, Randall C. Starling Tags: Brief Report Source Type: research

Contemporary Use of Venoarterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter RESCUE Registry
Mechanical circulatory support (MCS) devices are being increasingly used in the management of circulatory failure, growing 15-fold between 2007 and 2011.1 For cardiogenic shock specifically, MCS was used in approximately 23% of cases in 20142 and 34% of cases in 2019.3 The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO), in particular, has quadrupled in the last decade.4 (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 18, 2020 Category: Cardiology Authors: Rahul S. Loungani, Marat Fudim, Dave Ranney, Ajar Kochar, Marc D. Samsky, Desiree Bonadonna, Akinobu Itoh, Hiroo Takayama, Koji Takeda, Daniel Wojdyla, Adam D. DeVore, Mani Daneshmand Source Type: research

Intravenous Infusion of the β3-Adrenergic Receptor Antagonist APD418 Improves Left Ventricular Systolic Function in Dogs with Systolic Heart Failure
This study examined the e ffects of intravenous (i.v.) infusions of the β3-AR antagonist APD418 on cardiovascular function and safety in dogs with systolic heart failure (HF). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 18, 2020 Category: Cardiology Authors: Hani N. Sabbah, Kefei Zhang, Ramesh C. Gupta, Jiang Xu, Vinita Singh-Gupta, Michael Ma, Kathe Stauber, Nathalie Nguyen, John Adams Source Type: research

Exercise Tolerance in Patients Treated with a Durable Left Ventricular Assist Device: Importance of Myocardial Recovery
Prognosis in advanced heart failure (HF) is poor with a 1-year mortality of up to 50%. 1 Consequently, it is recommended that eligible patients are referred for evaluation for advanced HF therapies2. Heart transplantation (HTx) remains the gold standard therapeutic option in advanced HF. However, despite the use of older donors, the annual rates of HTx remain low, 3 challenging the needs of the increasing population of advanced HF patients. As a consequence, left ventricular assist device (LVAD) therapy has become an established treatment modality in this patient group, most commonly as bridge to transplantation (BTT) or d...
Source: Journal of Cardiac Failure - December 18, 2020 Category: Cardiology Authors: Nadia Paarup Dridi, Julie KK Vishram-Nielsen, Finn Gustafsson Tags: Review Article Source Type: research

Contemporary Use of Veno-Arterial ECMO: Insights from the Multi-Center RESCUE Registry
Mechanical circulatory support (MCS) devices are being increasingly utilized in the management of circulatory failure, growing 15-fold in the years between 2007 and 20111. For cardiogenic shock specifically, MCS was employed in approximately 23% of cases in 20142 and 34% of cases in 20193. Use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO), in particular, has quadrupled in the last decade4. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 18, 2020 Category: Cardiology Authors: Rahul S. Loungani, Marat Fudim, Dave Ranney, Ajar Kochar, Marc D. Samsky, Desiree Bonadonna, Akinobu Itoh, Hiroo Takayama, Koji Takeda, Daniel Wojdyla, Adam D. DeVore, Mani Daneshmand Source Type: research

Diuresis-Related Weight Loss Reflects Interstitial Compartment Decongestion with Minimal Impact on Intravascular Volume Expansion or Outcomes in Post-Acute Heart Failure
The development of symptomatic clinical congestion is the most common basis for hospitalization in patients with chronic heart failure (HF).1-2 The relief of congestion is, therefore, a central goal of intervention, and diuretic therapy is the mainstay to achieve that goal. The effectiveness of treatment is commonly based on improvement in symptoms and clinical assessment with change in body weight being a common metric used to assess adequacy of decongestive therapy. Thus, if weight loss reflects clinical decongestion and symptomatic improvement, this metric should also be associated with better post-hospital outcomes. (S...
Source: Journal of Cardiac Failure - December 18, 2020 Category: Cardiology Authors: Wayne L. Miller, Ronstan Lobo, Diane E. Grill, Brian P. Mullan Source Type: research

Delirium among Hospitalized Older Adults with Acute Heart Failure Exacerbation
: Delirium among older adults hospitalized with acute heart failure is associated with increased mortality. However, studies concomitantly assessing the association of delirium with both clinical and economic outcomes in this population, such as mortality, hospital cost or length of stay are lacking. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 18, 2020 Category: Cardiology Authors: Min Ji Kwak, Elenir Avritscher, Holly M. Holmes, Rachel Jantea, Renee Flores, Nahid Rianon, Tong Han Chung, Prakash Balan, Abhijeet Dhoble Source Type: research

Social Media as Ethical Obligation
Online behavior is in a state of rapid transition with the Internet at present evolving into a major source of medical information for the consumer1,2. It is critical that we in Cardiology are cognizant of this and comprehend the impact this has on consumer insight and on patient behavior and compliance. Two research letters in this issue highlight the potential application and opportunity of our understanding. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 17, 2020 Category: Cardiology Authors: Farris K. Timimi Tags: Editorial Comment Source Type: research

Social determinants of health and rates of implantation for patients considering destination therapy left ventricular assist device
Left ventricular assist device (LVAD) is a treatment option available to select patients with advanced heart failure.1 However, there are important social determinants of health (SDOH) that can play a role in determining patients ’ outcomes following device placement. Patients must typically have access to a specialized LVAD center, have health insurance to cover the cost of LVAD implantation, and have adequate financial resources to manage maintenance care and potential complications. LVAD programs also require patients h ave the support of a dedicated caregiver after the LVAD surgery. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 17, 2020 Category: Cardiology Authors: Kelsey Flint, Erin L. Chaussee, Kamal Henderson, Khadijah Breathett, Prateeti Khazanie, Jocelyn S. Thompson, Colleen K. McIlvennan, Shane J. LaRue, Daniel D. Matlock, Larry A. Allen Source Type: research

Intrarenal Venous Flow: A Distinct Cardiorenal Phenotype or Simply a Marker of Venous Congestion?
Over the past few decades, the pathophysiologic concept of heart failure (HF) has changed dramatically owing to an improved understanding of the condition as a systemic clinical syndrome characterized by the involvement of multiple organ systems, such as those involving the kidneys, lungs, liver, intestine, and brain, which leads to a multiorgan neurohormonal response and the activation of systemic inflammation.1 “Congestion,” whether hemodynamic or clinical in nature, is considered as a hallmark feature of HF, and accumulating evidence has revealed the pathophysiologic effect of congestion during the disease p...
Source: Journal of Cardiac Failure - December 7, 2020 Category: Cardiology Authors: Takeshi Kitai, W.H. Wilson Tang Tags: Editorial Source Type: research

Intrarenal Venous Flow: A Distinct Cardio-Renal Phenotype or Simply a Marker of Venous Congestion?
Over the past few decades, the pathophysiologic concept of heart failure has changed dramatically owing to an improved understanding of the condition as a systemic clinical syndrome characterized by the involvement of multiple organ systems, such as those involving the kidneys, lungs, liver, intestine, and brain, which leads to a multiorgan neurohormonal response and the activation of systemic inflammation.1 “Congestion,” whether hemodynamic or clinical in nature, is considered as a hallmark feature of heart failure, and accumulating evidence has revealed the pathophysiological effect of congestion during the d...
Source: Journal of Cardiac Failure - December 7, 2020 Category: Cardiology Authors: Takeshi Kitai, W.H. Wilson Tang Tags: Editorial Source Type: research

Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure
Acute kidney dysfunction is frequently observed in patients with acute heart failure (AHF). This has been termed worsening renal function (WRF), usually defined as a deterioration in kidney function reflected by increasing creatinine and decreasing glomerular filtration rate (GFR).1 –5 WRF has been variably associated with worse, neutral, or even improved outcomes.1–5 This variability is likely a product of different pathophysiologic processes driving alterations in renal function and potentially depends on whether acute tubular injury (ATI) is occurring. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 5, 2020 Category: Cardiology Authors: YU HORIUCHI, NICHOLAS WETTERSTEN, DIRK J. van VELDHUISEN, CHRISTIAN MUELLER, GERASIMOS FILIPPATOS, RICHARD NOWAK, CHRISTOPHER HOGAN, MICHAEL C. KONTOS, CHAD M. CANNON, GERHARD A. M ÜELLER, ROBERT BIRKHAHN, PAM TAUB, GARY M. VILKE, OLGA BARNETT, KENNETH M Source Type: research

Potential Utility of Cardio-Renal Biomarkers For Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure
Acute kidney dysfunction is frequently observed in patients with acute heart failure (AHF). This has been termed worsening renal function (WRF), usually defined as a deterioration in kidney function reflected by increasing creatinine and decreasing glomerular filtration rate (GFR) [1-5]. WRF has been variably associated with worse, neutral or even improved outcomes [1-5]. This variability is likely a product of different pathophysiologic processes driving alterations in renal function and potentially depends on whether acute tubular injury (ATI) is occurring [5]. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 5, 2020 Category: Cardiology Authors: Yu Horiuchi, Nicholas Wettersten, Dirk J. van Veldhuisen, Christian Mueller, Gerasimos Filippatos, Richard Nowak, Christopher Hogan, Michael C. Kontos, Chad M. Cannon, Gerhard A. M üeller, Robert Birkhahn, Pam Taub, Gary M. Vilke, Olga Barnett, Kenneth M Source Type: research

Editorial Board
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Source Type: research

Table of Contents
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Source Type: research

Masthead
(Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Source Type: research

Editorial Reflections
The former Presidential candidate Adlai Stevenson once famously said that an editor is someone who separates the wheat from the chaff and then prints the chaff. However, in my experience at the Journal of Cardiac Failure, it is more like separating the wheat from the wheat. The last six years have seen great progress. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Paul J. Hauptman Source Type: research

Excess 30-Day Heart Failure Readmission In Blacks Increases With Neighborhood Deprivation
Neighborhood socioeconomic status (SES) has been associated with incident heart failure (HF) as well as HF readmissions. Neighborhood SES may be particularly impactful for vulnerable populations. Hypothesis: Neighborhood SES modifies the disparity in 30-d HF readmissions between Black and White patients in the Southeastern US. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Shivani Anil Patel, Kaitlyn Long, Theresa E. Shirey, Neal J. Dickert, Alanna A. Morris Source Type: research

Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results From The Help-ph-hfpef Multicenter Randomized Controlled Trial
There is currently no effective treatment for patients with HFpEF and pulmonary hypertension (PH-HFpEF). We hypothesized that levosimendan (LEVO), a calcium sensitizer with inotropic and vascular smooth muscle relaxant properties, would improve hemodynamics and exercise capacity in PH-HFpEF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Barry A. Borlaug, Daniel Burkhoff, Sanjiv Shah, Ronald Zolty, Ryan Tedford, Thenappan Thenappan, Roham Zamanian, Jeremy Mazurek, Jonathan Rich, Marc Simon, Stuart Rich Source Type: research

Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy
We describe baseline guideline-directed medical therapy (GDMT) and examine if the primary outcome was associated with differences in adherence to GDMT including dosing. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Justin Ezekowitz, Ciaran McMullan, Cynthia Westerhout, Ileana L. Pina, Jose Lopez-Sendon, Kevin J. Anstrom, Adrian F. Hernandez, Carolyn S.P. Lam, Christopher M. O'Connor, Burkert Pieske, Piotr Ponikowski, Lothar Roessig, Adriaan A. Voors, Joerg Koglin, P Source Type: research

Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Emperial Trials
EMPA induces an initial decline in estimated glomerular filtration rate (eGFR) in T2D pts. Although considered hemodynamic and reversible, it may raise concerns in clinical practice. This phenomenon needs to be better understood in pts with HF, beyond T2D. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Stefan D. Anker, Piotr Ponikowski, Christoph Wanner, Egon Pfarr, Sibylle Hauske, Barbara Peil, Afshin Salsali, Ivana Ritter, Matias Nordaby, Audrey Koitka-Weber, Martina Brueckmann, Waheed Jamal, JoAnn Lindenfeld, William T. Abraham Source Type: research

Effect Of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients With Heart Failure With A Reduced Ejection Fraction, With And Without Sacubitril/valsartan
SGLT2 inhibitors reduce serious heart failure events in patients with type 2 diabetes, and one trial with dapagliflozin that enrolled patients with mild heart failure and a reduced ejection fraction has reported benefits in patients without diabetes. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Milton Packer Source Type: research

Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial
Sodium glucose cotransporter 2 inhibitors (SGLT2i) prevent heart failure (HF) in patients with Type 2 Diabetes (T2D), and reduce CV death or worsening HF in HF and reduced ejection fraction (HFrEF), regardless of T2D. Mechanisms of HF benefits are unclear, and effects of SGLT2i on filling pressures are not known. EMBRACE-HF was designed to address this knowledge gap. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Michael E. Nassif, Mohammed Qintar, Sheryl L. Windsor, Rita Jermyn, David M. Shavelle, Fengming Tang, Sumant Lamba, Kunjan Bhatt, John Brush, Andrew B. Civitello, Robert A. Gordon, Orvar Jonsson, Brent C. Lampert, Jamie Pelzel, Mikhail Kosiborod Source Type: research

Mechanistic Insight Into The Effect Of Spironolactone For Preventing Heart Failure: Proteomics And Knowledge-based Network Analysis From The Homage Trial
Further to their beneficial effects in established heart failure (HF), mineralocorticoid receptor antagonists may act upstream on mechanisms preventing incident HF. In people at risk for developing HF, the “Heart OMics in Aging” (HOMAGE) trial showed that spironolactone treatment could provide antifibrotic and anti-remodelling effects, potentially slowing the progression to HF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Joao Pedro Ferreira Source Type: research

A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction
In patients at high risk of heart failure (HF) following myocardial infarction (MI) as a result of residual left ventricular systolic dysfunction (LVSD), the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan may result in a greater attenuation of adverse LV remodeling than renin angiotensin aldosterone system inhibition alone, due to increased levels of substrates for neprilysin with vasodilatory, anti-hypertrophic, anti-fibrotic and sympatholytic effects. In a randomized, double-blinded, active-comparator trial, we examined the effect of sacubitril/valsartan compared with the angiotensin receptor blocker (ARB...
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Kieran F. Docherty, Ross T. Campbell, Katriona J.M. Brooksbank, Rosemary L. Godeseth, Paul Forsyth, Alex McConnachie, Giles Roditi, Bethany Stanley, Paul Welsh, Pardeep S. Jhund, Mark C. Petrie, John J.V. McMurray Source Type: research

Endovascular Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction - First-in-human Clinical Trial
In HFpEF, increased sympathetic outflow to the splanchnic venous system causes chronic redistribution of blood volume into the central circulation, which leads to exercise limitations, hemodynamic deterioration, and worsening outcomes. We have previously shown that surgical right greater splanchnic nerve (GSN) ablation in HFpEF leads to a reduction of PCWP, improved quality of life and exercise capacity. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: Sanjiv J. Shah, Teona Zirakashvili, Nikoloz Shaburishvili, Giorgi Shaishmelashvili, Horst Sievert, Kolja Sievert, Anisha Bapna, Zoar J. Engelman, Daniel Burkhoff, Tamaz Shaburishvili Source Type: research

Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)
Patients with chronic kidney disease (CKD) are at high risk of adverse renal and cardiovascular (CV) outcomes, particularly heart failure. We investigated the effects of dapagliflozin inpatients with CKD, with and without type 2 diabetes (T2D). DAPA-CKD is the first trial to test the effects of a SGLT2 inhibitor on renal and CV outcomes in CKD patients without T2D and included patients with a lower eGFR than in prior trials. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - December 1, 2020 Category: Cardiology Authors: John J.v. McMurray, David C. Wheeler, Bergur V. Stefansson, Ricardo Correa-Rotter, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Magnus B. Lindberg, Peter Rossing, C. David Sj öström, Robert D. Toto, Ann Maria Langkilde, Hiddo Jl Heerspink Source Type: research

Association Between Estimated Pulse Wave Velocity and the Risk of Heart Failure in the Kuopio Ischemic Heart Disease Risk Factor Study
Increased aortic stiffness, assessed as carotid-femoral pulse wave velocity (cfPWV), is associated with incident heart failure risk. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - November 24, 2020 Category: Cardiology Authors: Sae Young Jae, Kevin S. Heffernan, Sudhir Kurl, Setor K. Kunutsor, Jari A. Laukkanen Tags: Research Letter Source Type: research